Anixa Biosciences (NASDAQ:ANIX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $12.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 250.88% from the company’s current price.
Separately, TheStreet downgraded shares of Anixa Biosciences from a “c-” rating to a “d” rating in a research report on Friday, June 16th.
Anixa Biosciences Price Performance
Insider Transactions at Anixa Biosciences
In other news, CEO Amit Kumar sold 11,800 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $3.57, for a total transaction of $42,126.00. Following the completion of the transaction, the chief executive officer now directly owns 461,925 shares of the company’s stock, valued at approximately $1,649,072.25. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 20.40% of the company’s stock.
Institutional Trading of Anixa Biosciences
Several hedge funds and other institutional investors have recently bought and sold shares of ANIX. US Bancorp DE grew its stake in shares of Anixa Biosciences by 3,312.3% during the 1st quarter. US Bancorp DE now owns 13,649 shares of the company’s stock valued at $37,000 after buying an additional 13,249 shares during the period. Westside Investment Management Inc. purchased a new stake in shares of Anixa Biosciences during the 2nd quarter valued at $44,000. International Assets Investment Management LLC grew its stake in shares of Anixa Biosciences by 31.8% during the 1st quarter. International Assets Investment Management LLC now owns 14,500 shares of the company’s stock valued at $62,000 after buying an additional 3,500 shares during the period. Virtu Financial LLC purchased a new stake in shares of Anixa Biosciences during the 2nd quarter valued at $45,000. Finally, Simplicity Solutions LLC purchased a new stake in shares of Anixa Biosciences during the 1st quarter valued at $67,000. 11.78% of the stock is owned by hedge funds and other institutional investors.
Anixa Biosciences Company Profile
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.
- Five stocks we like better than Anixa Biosciences
- How to Buy Cheap Stocks Step by Step
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- What Are Meme Stocks and Are They Viable Investments?
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Consumer Discretionary Stocks Explained
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.